SEC Form 4 · accession 0001209191-15-074443
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jane Wasman
Officer — President, Intl and GC
Period of report
Oct 5, 2015
Accepted (ET)
Oct 6, 2015 · 8:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 5, 2015 | S | 531 | $30.9099 | D | 101,316 | D | |
| Common StockF1,F3 | Oct 5, 2015 | S | 3,219 | $31.8914 | D | 98,097 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $30.51 to $31.37 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $31.62 to $32.45 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.